Broxuridine
Alternative Names: BrdU; BrdUrd; BUdR; Neomark; NSC 38297Latest Information Update: 21 Aug 2019
At a glance
- Originator National Cancer Institute (USA)
- Developer INSYS Therapeutics, Inc; National Cancer Institute (USA)
- Class Antineoplastics; Antivirals; Diagnostic agents; Pyrimidine nucleosides; Radiation-sensitising agents; Radiosensitisers; Small molecules
- Mechanism of Action Antimetabolites; DNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Brain cancer; Breast cancer
Most Recent Events
- 30 Jan 2003 Discontinued - Phase-III for Brain cancer in Canada (IV)
- 30 Jan 2003 Discontinued - Preregistration for Brain cancer in USA (IV)
- 30 Jan 2003 Discontinued - Preregistration for Breast cancer diagnosis in USA (IV)